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Accepted 25 May 2011AbstractObjective: To explore the changes in placental gene expression between women with preeclampsia and those with superimposed preeclampsia on
chronic hypertension.
Materials and Methods: In Taiwanese population, we compared gene expression between the placentas from preeclamptic patients and those
with superimposed preeclampsia on chronic hypertension.
Results: Although top-ranked activated genes between preeclampsia and superimposed preeclampsia on chronic hypertension were different,
functional network analyses indicate that these genes are mainly involved in the regulation of cell death and apoptosis. These results suggest that
apoptosis and other types of cell death in the placenta are common consequences of both diseases. However, placental endoglin (ENG) was
expressed at a significantly higher level in preeclampsia than in superimposed preeclampsia. Results of functional network analysis indicated that
ENGmay play a role in the pathogenesis of preeclampsia through its interference with the endothelial nitric oxide synthase-regulated vasodilation.
Conclusion: Our results support the fact that ENG is the culprit for the development of preeclampsia. In addition, this study identifies several
other genes in the placenta, which are transcriptionally regulated in pregnancy-related hypertensions.
Copyright  2011, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All rights reserved.
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Preeclampsia is a multisystem disorder unique to human
pregnancy, and it occurs in 2e7% of nulliparous women [1]. It
is a major cause of maternal and neonatal death and morbidity
worldwide [2]. This condition, diagnosed by sustained de novo
hypertension and proteinuria after 20 weeks of gestation,
typically occurs in the third trimester of gestation. The
affected mother demonstrates increased blood pressure,
edema, proteinuria, abnormal clotting, and liver and renal* Corresponding authors. Department of Obstetrics and Gynecology, Chang
Gung Memorial Hospital, Lin-Kou Medical Center, Chang Gung University,
Tao-Yuan 333, Taiwan.
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doi:10.1016/j.tjog.2011.07.005dysfunction, whereas fetal preeclampsia syndrome can mani-
fest as preterm delivery; growth restriction; placental abrup-
tion; fetal distress; and, in some cases, fetal death [2].
Preeclampsia is caused by an adverse maternal response to
placentation. To date, however, no single theory could fully
explain the pathogenesis of preeclampsia [1]. Historically, two
opposing schools of thought have been the immunologists,
who consider preeclampsia as a maternal-embryonic immune
maladaptation [3e5], and the vascularists, who propose that
ischemia-reperfusion leads to oxidative stress and vascular
disease [6,7]. Both of these perspectives may be equally
important in a recent convergent model for preeclampsia
pathogenesis [8].
Pregnant women with chronic hypertension have an
increased risk of developing superimposed preeclampsia,cs & Gynecology. Published by Elsevier Taiwan LLC. All rights reserved.
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Although mixed presentations exist, two broad categories of
preeclampsia have been proposed: placental and maternal [8].
In placental preeclampsia, to which pure preeclampsia belongs,
the syndrome arises from placenta under oxidative stress.
Maternal preeclampsia arises from the interaction between
a normal placenta and a maternal constitution that is susceptible
to microvascular diseases, such as hypertension or diabetes.
Chronic hypertension with superimposed preeclampsia most
likely belongs to maternal preeclampsia. With reference to the
aforementioned two-stage process of preeclampsia, super-
imposed preeclampsia might skip the first stage of the immune-
related faulty placentation process to start off at the second
stage of the vasoconstriction-causing placental ischemia
process. However, it remains unknown whether placental
preeclampsia and maternal preeclampsia operate from distinct
molecular mechanisms.
Given that preeclampsia is of placental origin, it is sensible
to compare the gene expression profiles of placentas among
pregnant patients with preeclampsia, those with chronic
hypertension with superimposed preeclampsia, and normal
controls, to understand the pathogenesis of different types of
preeclampsia [9]. In this study of Taiwanese women, we
analyzed distinct groups of differentially expressed genes and
their corresponding functional networks among the placentas
collected from women with normal pregnancies, preeclampsia,
and superimposed preeclampsia on chronic hypertension.
MethodsExperimental designs and inclusion criteria of the
parturientIn this study, 30 cases were included: 10 women in the
scheduled cesarean section (CS) group, 13 in the preeclampsia
group, and seven in the superimposed preeclampsia on
hypertension group. We obtained written informed consent
from all participating women. This study has been approved
by Institute Review Board of Chang Gung Memorial Hospital
(No. 96-0630B).
Preeclampsia was diagnosed in the presence of hyperten-
sion and proteinuria [1]. Hypertension is defined as a blood
pressure higher than 140 mmHg (systolic) or 90 mmHg (dia-
stolic) on at least two occasions at least 4e6 hours apart.
Proteinuria is defined as the excretion of greater than 300 mg
protein within 24 hours or a protein concentration of 300 mg/L
or more (>1þ on dipstick) in at least two random urine
samples taken at least 4e6 hours apart [1]. When a woman
was documented as hypertensive before 20th week of gesta-
tion, she was considered to have chronic hypertension.
Preeclampsia superimposed on chronic hypertension is defined
by worsening hypertension and proteinuria occurring in
women with documented chronic hypertension [10]. Addi-
tional criteria for superimposed preeclampsia include
proteinuria development; neurological symptoms, such as
severe headaches and visual disturbances; generalized patho-
logical edema; oliguria; pulmonary edema; increased serumcreatinine; thrombocytopenia; and appreciable elevations of
serum hepatic transaminase.Specimen collection and processingImmediately after delivery of placentas, four pieces (about
0.5 cm 0.5 cm 0.5 cm each) of placental tissue were cut
from the maternal side of placenta, snap frozen in liquid
nitrogen, and stored at 80C.RNA isolation and DNA microarray experimentsWe used Trizol and RNA Easy kit (Qiagen, Valencia, CA,
USA) to isolate RNA from placental tissues. The quality and
quantity of total RNA were evaluated with Agilent Bio-
analyzer 2100 (Agilent Technologies Inc., Palo Alto, CA,
USA). Detailed information in Minimal Information About
a Microarray Experiment format [11,12] from the Genomic
Medicine Research Core Laboratory Human 15K chips can
be accessed at the Website http://www.cgmh.org.tw/intr/intr2/
c32a0/chinese/corelab_intro/genetics/index_1.htm. We used
2-mg total RNA for labeling and hybridization using the 3DNA
Array 350RP Detection kit (Genisphere, PA, USA); scanned
slides with amicroarray scanner (Axon Instruments, Inc., Foster
City, CA, USA); and acquired spot and background intensities
with GenePix Pro 4.1 software (Axon Instruments, Inc.).Microarray data analysisTo carry out within-slide normalization, we used a local
weighted regression (www.stat.berkeley.edu/users/terry/zarray/
Html/soft.htm) method in which changes of intensity were
assumed to be symmetrical for all spots. Thus, normalization
was performed in each bin of spots, as previously described
[13e16].
Using the matrix transformation [17], the expression level
of each gene in individual placental samples was represented
as the fold change relative to that of a virtual common refer-
ence. For statistical analyses of each gene expression level,
Mann-Whitney U tests were used with Statistica version 6.1
(Statsoft Inc, Tulsa, OK, USA). Chi-square analysis was used
for the study of fetal sex in various groups of placental origins.
A p value less than 0.05 was used to determine statistical
significance.Network visualization and analysisNetwork analyses of differentially expressed genes were
performed using MetaCore Analytical Suite (GeneGo Inc,
St Joseph, MI, USA) [18,19]. MetaCore is a Web-based
computational platform designed for systems biology and
drug discovery. It includes a curated database of human
protein interactions and metabolism; hence, it is useful for
analyzing a cluster of genes in the context of regulatory
networks and signaling pathways. For the network analysis of
a group of genes, MetaCore can be used to calculate the
statistical significance (p value) based on the probability of
Table 2
Top-ranked expressed genes in hypertension-related diseases
Ctr> PE Ctr< PE Ctr> Super Ctr< Super PE> Super PE< Super
RNF128 PAF53 FOXP2 ATBF1 HADH2 LGALS14
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as the input list [19].
Results
ADM HSPA1B LHPP TGFBI HNRPA1 HSD17B2
ARFIP1 SLC2A6 PRSS16 VPREB3 C11orf24 TPPP3
SOD1 LIMS1 ACVR1 CRIP2 MT1A CCAR1
RNASE1 FAM53B ZNF397 INDO AADAC KCNV1Demographics of the 30 patients included in the
hypertensive disorder analysis (Table 1)CLDN1 CDC42EP1 ABCC2 PRAME PAF53 SIAH1
PRPF31 PLAGL1 PEA15 KIAA0194 HIST1H4J PRDX4
FIGF RNF149 AKAP9 POGZ CDC42EP1 MAN1A2
BGR4 RPUSD3 DUSP11 SIRT4 NALP11 SGPP1
PAPPA KIF19 ISYNA1 TEAD3 KIAA0141 ANK3
HSPA14 SLC35D1 PROC ABHD2 DCAF4L2 SELO
NR2C1 DAP4 MT1G SLC30A5 RNPC7 ELA3A
VPS39 TRIM31 SFTPC UBADC1 G6PD ZNF430
MAPK8IP2 FBXO26 BAAT PXMP4 KIAA0895 UBXD2
FKBP1A PSCD4 RPS4X PPM1F TSPAN33 FAM63B
FNDC3A UROS TCFL5 IST1H2BC RPL24 SH3GLB2
GANAB FLJ25006 TBL3 ZNF22 ENG LIME1
ADAM10 ANKR TUBB2A CDT1 CD48 TRH
NEO1 PPP2R2C TTC7A PWP1 CHI3L1 CCNG1
CHDC1 MFAP1 STAT3 MGC2803 PLEKHH1 CAST
Ctr¼ controls; PE¼ preeclampsia; Super¼ superimposed preeclampsia.Maternal ages in the CS group were greater than those in
the preeclampsia group. Ages in mothers with normal cesarean
and superimposed preeclampsia were greater than those of the
preeclampsia group. Gestational ages in preeclampsia and
superimposed preeclampsia groups were significantly lower
than those in the CS group, because the most common reasons
for preterm deliveries in the preeclampsia and superimposed
preeclampsia groups were fetal distress and uncontrollable
maternal hypertension. Likewise, fetal body weights in the
preeclampsia and superimposed preeclampsia groups were
significantly less than those in the CS group.
Blood pressures during early pregnancy (less than 20
gestational weeks) were not statistically different between
women with normal pregnancy and those with preeclampsia.
Likewise, blood pressures in these two groups were not statis-
tically different during the postpartum period. On the other
hand, blood pressures at delivery were significantly elevated in
women with preeclampsia and in those with superimposed
preeclampsia on chronic hypertension (p< 0.0001). During the
postpartum period, blood pressures in the preeclampsia group
returned to normal, whereas those in the superimposed
preeclampsia group remained hypertensive (p< 0.0001).Functional network analyses of differentially expressed
genesTo identify differentially expressed genes in preeclampsia
and superimposed preeclampsia, we used local weighted
regression algorithm to normalize gene expression levels in each
microarray, and nonparametric statistics and Mann-Whitney UTable 1
Demographics of the parturient in the hypertensive disorder analysis (n¼ 30)
Clinical information CS (n¼ 10) Preeclam
Maternal age (y) 33.2 1.61,2 28.1 1
Gravida 2.3 0.5 1.5 0
Para 2.0 0.3 1.4 0
GA (wk) 38.8 1.05,6 33.5 0
BW (g) 3270 2629,10 1666 2
Systolic BP at GA <20 wk 109 4.213,14 121 3
Diastolic BP at GA <20 wk 62 3.114 70 2
Systolic BP at labor 112 4.414 177 3
Diastolic BP at labor 61 3.514 104 3
Systolic BP, postpartum 114 3.514 120 2
Diastolic BP, postpartum 63 3.014 77 2
Data are presented as mean standard error.
Statistical values were derived from post hoc comparisons: 1p¼ 0.010; 2p¼ 0.02
9p¼ 0.0002; 10p¼ 0.013; 11p¼ 0.00004; 12p¼ 0.004; 13p¼ 0.039; 14p< 0.0001; 1
a One-way analysis of variance was used for statistics in this table.
BP¼ blood pressure; BW¼ fetal body weight; CS¼ cesarean section; GA¼ gesta
Boldfaced p values are those less than 0.05.test to compare the expression levels of each gene. Twenty top-
ranked differentially expressed genes of each comparison are
listed in Table 2. Gene identification number, gene name,
p values of Mann-Whitney U test, and fold changes in the
columns titled as Ctr< PE, Ctr< Super, and PE> Super
(Table 2) are further summarized in Tables 3e5.
To study the functions of differentially expressed genes in
diseases, we analyzed the genes in Tables 3e5 with MetaCore
analysis software and database (www.genego.com). Functional
network analyses of these lists included the genes that were
upregulated in preeclampsia (Fig. 1), those upregulated in
superimposed preeclampsia (Fig. 2), and those expressed at a
higher level in preeclampsia than in superimposed preeclampsia
(Fig. 3). The placental genes that were upregulated in the
placentas with preeclampsia (HSPA1B, LIMS1, PLAGL1,
TRIM31, PPP2R2C ) (Table 3) and those in superimposedpsia (n¼ 13) Superimposed p (n¼ 7) Overall pa
.42,3 33.5 1.93,4 0.015
.4 2.8 0.6 0.329
.3 2.0 0.4 0.261
.95,7 34.2 1.26,8 0.0005
279,11 2132 32110,12 0.0009
.713,14 155 5.214,15 <0.0001
.714 95 3.814 <0.0001
.814 167 5.414 <0.0001
.014 106 4.314 <0.0001
.814 149 3.314 <0.0001
.614 101 3.714 <0.0001
5; 3p¼ 0.033; 4p¼ 0.014; 5p¼ 0.0006; 6p¼ 0.009; 7p¼ 0.0005; 8p¼ 0.007;
5p< 0.0001.
tional age.
Table 3
Top-ranked genes overexpressed in preeclampsia
Gene symbol Gene ID Gene name U test Fold change
PAF53 64425 RNA polymerase I associated factor 53 0.002 1.3
HSPA1B 3304 Heat shock 70 kDa protein 1B 0.018 1.2
SLC2A6 11182 Solute carrier family 2 (facilitated glucose transporter), member 6 0.029 1.2
LIMS1 3987 LIM and senescent cell antigen-like domains 1 0.002 1.2
FAM53B 9679 Family with sequence similarity 53, member B 0.010 1.2
CDC42EP1 11135 CDC42 effector protein (Rho GTPase binding) 1 0.028 1.2
PLAGL1 5325 Pleiomorphic adenoma gene-like 1 0.039 1.2
RNF149 284996 Ring finger protein 149 0.043 1.2
RPUSD3 285367 RNA pseudouridylate synthase domain containing 3 0.045 1.2
KIF19 124602 Kinesin family member 19 0.006 1.1
SLC35D1 23169 Solute carrier family 35, member D1 0.015 1.1
DAP4 22839 Disks large-associated protein 4 0.004 1.1
TRIM31 11074 Tripartite motif-containing 31 0.023 1.1
FBXO26 115290 F-box only protein 26 0.016 1.1
PSCD4 27128 Pleckstrin homology, Sec7 and coiled-coil domains 4 0.037 1.1
UROS 7390 Uroporphyrinogen III synthase (congenital erythropoietic porphyria) 0.009 1.1
FLJ25006 124923 Hypothetical protein FLJ25006 0.035 1.1
ANKR 150709 Ankyrin and armadillo repeat containing 0.032 1.1
PPP2R2C 5522 Protein phosphatase 2, regulatory subunit B (PR 52), gamma isoform 0.037 1.1
MFAP1 4236 Microfibrillar-associated protein 1 0.009 1.1
Gene ID¼Gene identification number.
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HIST1H2BC, CDT1) (Table 4) are mainly involved in the
regulation of apoptosis and other types of cell death (Table 6).
Of note, the genes that were expressed at a significantly higher
level in preeclampsia than in superimposed preeclampsia on
chronic hypertension were HNRPA1, G6PD, and ENG (Table 5
and Fig. 3).
Discussion
The placenta plays a central role in fetal and maternal
physiology [5]. Not surprisingly, its dysfunctions result inTable 4
Top-ranked genes overexpressed in superimposed preeclampsia
Gene symbol Gene ID Gene name
ATBF1 463 AT-binding transcription factor 1
TGFBI 7045 Transforming growth factor, beta
VPREB3 29802 Pre-B lymphocyte gene 3
CRIP2 1397 Cysteine-rich protein 2
INDO 3620 Indoleamine-pyrrole 2,3 dioxyge
PRAME 23532 Preferentially expressed antigen
KIAA0194 22993 KIAA0194 protein
POGZ 23126 Pogo transposable element with
SIRT4 23409 Sirtuin (silent mating type inform
TEAD3 7005 TEA domain family member 3
ABHD2 11057 Abhydrolase domain containing
SLC30A5 64924 Solute carrier family 30 (zinc tra
UBADC1 10422 Ubiquitin associated domain con
PXMP4 11264 Peroxisomal membrane protein 4
PPM1F 9647 Protein phosphatase 1F (PP2C d
HIST1H2BC 8347 Histone 1, H2bc
ZNF22 7570 Zinc finger protein 22 (KOX 15
CDT1 81620 DNA replication factor
PWP1 11137 Nuclear phosphoprotein similar
MGC2803 79002 Hypothetical protein MGC2803
Gene ID¼Gene identification number.various disorders, such as preeclampsia during pregnancy,
coronary heart disease in the later life of the mother, and
intrauterine growth restriction and preterm labor of the fetus
[1,2,20]. With the advent of genome-wide high-throughput
research tools, such as DNA microarrays [13,21], gene
expression patterns in the human placenta have been recently
explored, demonstrating systemic differences of gene expres-
sion profiles among the maternal, fetal, and intermediate
layers of the placenta [20].
When DNA microarrays are used to analyze similar tissues,
gene expression profiles obtained from different studies have
been notoriously varied and even occasionally conflicting. TheU test Fold change
0.027 1.7
-induced, 68 kDa 0.027 1.7
0.014 1.5
0.029 1.3
nase 0.008 1.3
in melanoma 0.033 1.3
0.006 1.3
ZNF domain 0.025 1.3
ation regulation 2 homolog) 4 0.048 1.2
0.017 1.2
2 0.038 1.2
nsporter), member 5 0.041 1.2
taining 1 0.017 1.2
, 24 kDa 0.036 1.2
omain containing) 0.034 1.2
0.036 1.2
) 0.014 1.2
0.010 1.2
to S cerevisiae PWP1 0.031 1.2
0.013 1.2
Table 5
Top-ranked genes that expressed at a higher level in preeclampsia than in superimposed preeclampsia
Gene symbol Gene ID Gene name U test Fold change
HADH2 3028 Hydroxyacyl-coenzyme A dehydrogenase, Type II 0.004 2.0
HNRPA1 3178 Heterogeneous nuclear ribonucleoprotein A1 0.012 1.5
C11orf24 53838 Chromosome 11 open reading frame 24 0.033 1.4
MT1A 4489 Metallothionein 1A (functional) 0.029 1.4
AADAC 13 Arylacetamide deacetylase (esterase) 0.028 1.3
PAF53 64425 RNA polymerase I associated factor 53 0.008 1.3
HIST1H4J 8363 Histone 1, H4j 0.036 1.3
CDC42EP1 11135 CDC42 effector protein (Rho GTPase binding) 1 0.009 1.3
NALP11 204801 NACHT, leucine rich repeat and PYD containing 11 0.002 1.3
KIAA0141 9812 KIAA0141 gene product 0.030 1.3
DCAF4L2 138009 DDB1 and CUL4 associated factor 4-like 2 0.017 1.3
RNPC7 58517 RNA-binding region (RNP1, RRM) containing 7 0.046 1.3
G6PD 2539 Glucose-6-phosphate dehydrogenase 0.025 1.3
KIAA0895 23366 KIAA0895 protein 0.014 1.3
TSPAN33 340348 Tetraspanin 33 0.019 1.3
RPL24 6152 Ribosomal protein L24 0.041 1.3
ENG 2022 Endoglin (Osler-Rendu-Weber syndrome 1) 0.017 1.3
CD48 962 CD48 antigen (B-cell membrane protein) 0.013 1.2
CHI3L1 1116 Chitinase 3-like 1 (cartilage glycoprotein-39) 0.003 1.2
PLEKHH1 57475 Pleckstrin homology domain containing, family H member 1 0.010 1.2
Gene ID¼Gene identification number.
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platforms, nonuniform coverage of gene sets, distinct data-
filtering strategies, various statistical stringencies, and data
complexity and variability [22e24]. It is, therefore, not
surprising that the most differentially expressed genes between
normal and preeclamptic placentas in our study were quite
different from those of a recent report [25]. In addition to the
aforementioned factors, the discrepancy between two studiesFig. 1. Network analysis of the genes upregulated (overexpressed) in preeclampsi
placentas with preeclampsia. Green lines indicate stimulation, whereas red lines inmay also result from the different gestational ages of controls
used. Soleymanlou et al [25] compared preeclamptic placentas
with those of age-matched controls, and they admitted that the
age-matched controls apparently suffered from preterm labor
and were not healthy controls. On the other hand, our controls
had normal term pregnancies, though not age matched. Given
that most cases of preeclampsia end up with preterm delivery,
it is impossible to compare gene expression obtained from thea. Genes in blue circles are the root genes that exhibited upregulation in the
dicate inhibition.
Fig. 2. Network analysis of the genes upregulated (overexpressed) in superimposed preeclampsia. Genes in blue circles are the root genes that exhibited upre-
gulation in the placentas with superimposed preeclampsia. Green lines indicate stimulation, whereas red lines indicate inhibition.
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age-matched control group [25]. Nevertheless, the consistency
of our results on endoglin (ENG) with recent reports validates
the quantification of microarray system in this study [26e28].
Among the placental factors that might contribute to the
pathogenesis of preeclampsia, ENG has been recently proposed
as a placenta-derived soluble transforming growth factor-beta
(TGF-b) coreceptor [28]. ENG is elevated in the sera of
preeclamptic women; its levels fall after delivery and correlate
with disease severity [28]. There was only a mild, though
statistically significant, difference in the ENG expression levels
between the placentas with preeclampsia and those with
chronic hypertension (Table 5). As shown by Reddy et al
[26], the ENG levels in both normal and preeclamptic
patients decline significantly 24 hours after delivery. The
serum levels of ENG in women with preeclampsia dropped
rapidly 10 minutes after CS. Our identification of a mild but
significantly higher expression level of ENG in the placentas
with preeclampsia was consistent with the phenomenon
observed [26].
We have been using MetaCore database and software to
understand the collaborating functions of groups of genes,
which were derived from DNA microarrays [29,30] or pro-
teomics [31,32]. The network generation of MetaCore is based
on a frequently updated database, in which each connection
between two molecules is established from direct physical
interactions between active proteins in human cells using
information extracted from experimental literature [19]. In thisstudy, we first selected a list of significantly differentiated
expressed genes, which might represent a signature profile for
the disease. Then we analyzed those genes based on the
database of protein-protein interactions, producing disease-
specific functional signature networks consisting of func-
tional pathways organized into a topology tailored for a given
condition.
When comparing the functional processes exerted by the
upregulated genes in the placentas between preeclampsia
and superimposed preeclampsia, most of them are similard
regulation of apoptosis, cell death, and programmed cell death
(Table 6). These results suggest that apoptosis and other types
of cell death in the placenta are common consequences of both
diseases. Because gestational ages were significantly different
between normal pregnancy (about 38e39 weeks) and preg-
nancies complicated with hypertension (about 33e34 weeks)
(Table 1), we could not completely rule out the possibility that
differential gene expression between normal and preeclamptic
pregnancies might partially result from different gestational
ages. On the other hand, there was no significant difference in
gestational ages between preeclampsia and chronic hyperten-
sion with superimposed preeclampsia (Table 1). Therefore, no
such confounding factors existed when comparing expression
profiles between preeclampsia and superimposed preeclampsia
on chronic hypertension.
Based on the results of network analysis (Fig. 3), HNRPA1,
G6PD, and ENG were involved in the pathogenesis of
preeclampsia. To our knowledge, there is no association
Fig. 3. Network analysis of the genes highly expressed in preeclampsia when compared with superimposed preeclampsia (preeclampsia> superimposed
preeclampsia). Genes in blue circles are the root genes that expressed at a significantly higher level in the placentas with preeclampsia than in those with
superimposed preeclampsia. Green lines indicate stimulation, whereas red lines indicate inhibition.
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unclear. The presence of G6PD in both normal and
preeclampsia placentas suggests its role in the carbohydrate
metabolism of the human placenta [33]. More recently,
decreased G6PD activity in preeclampsia was found to be
associated with impaired redox regulation in erythrocytes and
fetal endothelial cells [34].
On the other hand, ENG activates eNOS [35,36] as well as
interacts and modulates Activin receptor-like kinase-1 and -5Table 6
Functional analyses of genes that were upregulated in the placentas with preeclamp
Upregulated in preeclampsia
Process p
Regulation of developmental process 3.98E-16
Regulation of apoptosis 5.38E-16
Regulation of cell death 7.01E-16
Regulation of programmed cell death 7.01E-16
Positive regulation of biological process 4.24E-14
Regulation of catalytic activity 1.19E-13
Regulation of molecular function 1.30E-13
Positive regulation of cellular process 4.40E-13
Negative regulation of apoptosis 5.23E-13
Negative regulation of programmed cell death 6.64E-13
E¼ exponential function.signaling [36], resulting in the potentiation of Smad1 and
Smad2 and inhibition of Smad3 [36,37], thereby disrupting
homeostasis and causing the development of preeclampsia
[36]. Venkatesha et al [28] found that ENG decreases the
arterial diameter of rat renal microvessels when modulating
TGF-b1 and TGF-b3 mediated vasodilation. Subsequently,
ENG blocks TGF-b1-mediated activation of eNOS. In human
umbilical vein endothelial cells in vitro, soluble ENG coop-
erates with soluble fms-like tyrosine kinase 1 to inducesia and those with superimposed preeclampsia according to MetaCore database
Upregulated in superimposed preeclampsia
Process p
Positive regulation of biological process 6.91E-14
Regulation of developmental process 4.49E-13
System development 2.81E-12
Regulation of cell death 3.52E-12
Regulation of programmed cell death 3.52E-12
Positive regulation of cellular process 3.95E-12
Organ development 1.19E-11
Anatomical structure development 2.12E-11
Regulation of apoptosis 2.92E-11
Multicellular organismal development 6.65E-11
290 S.-D. Chang et al. / Taiwanese Journal of Obstetrics & Gynecology 50 (2011) 283e291endothelial dysfunction, and simultaneous administration of
both to rats causes a severe preeclampsia-like illness in vivo
[28,38,39]. Collectively, our results suggest that ENG may
play a role in the pathogenesis of preeclampsia through its
interference with the eNOS-regulated vasodilation.
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